Literature DB >> 27668233

Skin communicates what we deeply feel: antibiotic prophylactic treatment to reduce epidermal growth factor receptor inhibitors induced rash in lung cancer (the Pan Canadian rash trial).

Oscar Arrieta1, Amir Carmona2, Maria Teresa de Jesus Vega3, Mariana Lopez-Mejia1, Andrés F Cardona4.   

Abstract

Entities:  

Year:  2016        PMID： 27668233      PMCID： PMC5009032          DOI： 10.21037/atm.2016.08.19

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  21 in total

1.  Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.

Authors:  Emma Guttman-Yassky; Alain Mita; Maja De Jonge; Lesley Matthews; Sean McCarthy; Kenneth K Iwata; Jaap Verweij; Eric K Rowinsky; James G Krueger
Journal:  Eur J Cancer       Date:  2010-06-02       Impact factor: 9.162

Review 2.  Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management.

Authors:  Jenny C Hu; Parrish Sadeghi; Lauren C Pinter-Brown; Sharona Yashar; Melvin W Chiu
Journal:  J Am Acad Dermatol       Date:  2006-12-01       Impact factor: 11.527

3.  Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer.

Authors:  Mario E Lacouture; Edith P Mitchell; Bilal Piperdi; Madhavan V Pillai; Heather Shearer; Nicholas Iannotti; Feng Xu; Mohamed Yassine
Journal:  J Clin Oncol       Date:  2010-02-08       Impact factor: 44.544

4.  Randomized, open-label trial evaluating the preventive effect of tetracycline on afatinib induced-skin toxicities in non-small cell lung cancer patients.

Authors:  Oscar Arrieta; María Teresa Vega-González; Diego López-Macías; Jorge Negueb Martínez-Hernández; Ludwing Bacon-Fonseca; Eleazar Omar Macedo-Pérez; Laura Alejandra Ramírez-Tirado; Diana Flores-Estrada; Jaime de la Garza-Salazar
Journal:  Lung Cancer       Date:  2015-03-28       Impact factor: 5.705

5.  Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB).

Authors:  Aminah Jatoi; Shaker R Dakhil; Jeff A Sloan; John W Kugler; Kendrith M Rowland; Paul L Schaefer; Paul J Novotny; Donald B Wender; Howard M Gross; Charles L Loprinzi
Journal:  Support Care Cancer       Date:  2010-09-06       Impact factor: 3.603

6.  Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer.

Authors:  Barbara Melosky; Helen Anderson; Ronald L Burkes; Quincy Chu; Desiree Hao; Vincent Ho; Cheryl Ho; Wendy Lam; Christopher W Lee; Natasha B Leighl; Nevin Murray; Sophie Sun; Robert Winston; Janessa J Laskin
Journal:  J Clin Oncol       Date:  2015-11-16       Impact factor: 44.544

7.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Authors:  Lecia V Sequist; James Chih-Hsin Yang; Nobuyuki Yamamoto; Kenneth O'Byrne; Vera Hirsh; Tony Mok; Sarayut Lucien Geater; Sergey Orlov; Chun-Ming Tsai; Michael Boyer; Wu-Chou Su; Jaafar Bennouna; Terufumi Kato; Vera Gorbunova; Ki Hyeong Lee; Riyaz Shah; Dan Massey; Victoria Zazulina; Mehdi Shahidi; Martin Schuler
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544

8.  Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.

Authors:  James Chih-Hsin Yang; Vera Hirsh; Martin Schuler; Nobuyuki Yamamoto; Kenneth J O'Byrne; Tony S K Mok; Victoria Zazulina; Mehdi Shahidi; Juliane Lungershausen; Dan Massey; Michael Palmer; Lecia V Sequist
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544

Review 9.  Dermatologic adverse events associated with afatinib: an oral ErbB family blocker.

Authors:  Mario E Lacouture; Dirk Schadendorf; Chia-Yu Chu; Martina Uttenreuther-Fischer; Uz Stammberger; Dennis O'Brien; Axel Hauschild
Journal:  Expert Rev Anticancer Ther       Date:  2013-03-18       Impact factor: 4.512

10.  Histopathology of acneiform eruptions in patients treated with epidermal growth factor receptor inhibitors.

Authors:  Lindsey A Brodell; Donna Hepper; Anne Lind; Alejandro A Gru; Milan J Anadkat
Journal:  J Cutan Pathol       Date:  2013-08-14       Impact factor: 1.587
View more
  1 in total

1.  Cutaneous Toxicities of Molecular Targeted Therapies.

Authors:  Dana Lucia Stanculeanu; Daniela Zob; Oana Catalina Toma; Bogdan Georgescu; Laura Papagheorghe; Raluca Ioana Mihaila
Journal:  Maedica (Bucur)       Date:  2017-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.